Processing

Please wait...

Settings

Settings

Goto Application

1. WO2021174142 - RECOMBINANT POXVIRUS BASED VACCINE AGAINST SARS-COV-2 VIRUS

Publication Number WO/2021/174142
Publication Date 02.09.2021
International Application No. PCT/US2021/020119
International Filing Date 26.02.2021
IPC
A61K 39/215 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
215Coronaviridae, e.g. avian infectious bronchitis virus
C07K 14/165 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
08RNA viruses
165Coronaviridae, e.g. avian infectious bronchitis virus
C12N 15/863 2006.1
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
79Vectors or expression systems specially adapted for eukaryotic hosts
85for animal cells
86Viral vectors
863Poxviral vectors, e.g. vaccinia virus
CPC
A61K 2039/5256
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
51comprising whole cells, viruses or DNA/RNA
525Virus
5256expressing foreign proteins
A61K 2039/572
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
57characterised by the type of response, e.g. Th1, Th2
572cytotoxic response
A61K 2039/70
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
70Multivalent vaccine
A61K 39/12
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
A61K 39/215
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
215Coronaviridae, e.g. avian infectious bronchitis virus
A61P 31/14
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12Antivirals
14for RNA viruses
Applicants
  • TONIX PHARMACEUTICALS HOLDING CORP. [US]/[US]
  • THE GOVERNORS OF THE UNIVERSITY OF ALBERTA [CA]/[CA]
  • GOEBEL, Scott, J. [US]/[US]
  • EVANS, David [CA]/[CA]
  • NOYCE, Ryan [CA]/[CA]
Inventors
  • GOEBEL, Scott, J.
  • EVANS, David
  • NOYCE, Ryan
  • LEDERMAN, Seth
Agents
  • HALEY, James, F., Jr.
  • MANGASARIAN, Karen
  • GUMMOW, Brian, M.
Priority Data
62/981,99726.02.2020US
63/114,51416.11.2020US
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) RECOMBINANT POXVIRUS BASED VACCINE AGAINST SARS-COV-2 VIRUS
(FR) VACCIN À BASE DE POXVIRUS RECOMBINANT CONTRE LE VIRUS SARS-COV-2
Abstract
(EN) The invention relates in various aspects to a recombinant poxvirus comprising a nucleic acid encoding a SARS-CoV-2 virus protein, methods for producing such viruses and the use of such viruses. The recombinant poxviruses are well suited, among others, as protective virus vaccines against SARS-CoV-2 virus.
(FR) L'invention concerne, selon divers aspects, un poxvirus recombinant comprenant un acide nucléique codant pour une protéine du virus du SARS-CoV-2, des méthodes de production de tels virus et l'utilisation de tels virus. Les poxvirus recombinants sont bien appropriés, entre autres, en tant que vaccins viraux de protection contre le virus du SARS-CoV-2.
Latest bibliographic data on file with the International Bureau